


To obtain a broadly based exposure to European equity markets., focusing on sectoral rather than country asset allocation.
| Name | % Net Assets |
|---|---|
| Total | 4.5% |
| Sanofi-Aventis | 2.9% |
| Novartis | 2.8% |
| Roche Holdings | 2.6% |
| ENI | 2.6% |
| Deutsche Telekom | 2.5% |
| BNP Paribas | 2.5% |
| UBS AG | 2.1% |
| Telefonica | 2.0% |
| ABM-Amro Holdings | 1.9% |
| Key | % Net Assets |
|---|---|
| 4.5% | |
| 2.9% | |
| 2.8% | |
| 2.6% | |
| 87.2% |
| Date | 04-Dec-2024 |
|---|---|
| NAV | 374.80p |
| Currency | GBP |
| Change | -1.50p |
| % | -0.40% |
| YTD change | 374.80p |
| YTD % | n/a |
| Fund Inception | 01/03/1987 |
|---|---|
| Fund Manager | Stuart Fraser |
| TER | - |
| Minimum Investment | |
|---|---|
| Initial | £500 |
| Additional | n/a |
| Savings | £50 |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | n/a |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.13 |
You are here: research